{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T19:14:34Z","timestamp":1786994074629,"version":"build-2736575974"},"reference-count":59,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2014,9,1]],"date-time":"2014-09-01T00:00:00Z","timestamp":1409529600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Medicina Cl\u00ednica"],"published-print":{"date-parts":[[2014,9]]},"DOI":"10.1016\/j.medcli.2013.09.034","type":"journal-article","created":{"date-parts":[[2013,12,15]],"date-time":"2013-12-15T11:16:00Z","timestamp":1387106160000},"page":"222-229","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Antiagregaci\u00f3n: resistencia a f\u00e1rmacos tradicionales y papel de los nuevos antiplaquetarios"],"prefix":"10.1016","volume":"143","author":[{"given":"Hugo","family":"del Castillo-Carnevali","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivencio","family":"Barrios Alonso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Luis","family":"Zamorano G\u00f3mez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.medcli.2013.09.034_bib0005","doi-asserted-by":"crossref","first-page":"340","DOI":"10.2174\/1574884711308040008","article-title":"Poor response to antiplatelet drugs. An Important issue in drug-eluting stents","volume":"8","author":"Del Castillo-Carnevali","year":"2013","journal-title":"Curr Clin Pharmacol"},{"key":"10.1016\/j.medcli.2013.09.034_bib0010","doi-asserted-by":"crossref","first-page":"e362","DOI":"10.1161\/CIR.0b013e3182742cf6","article-title":"2013 ACCF\/AHA guideline for the management of ST-elevation myocardial infarction: a report of the CB American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines","volume":"127","author":"O\u2019Gara","year":"2013","journal-title":"Circulation"},{"key":"10.1016\/j.medcli.2013.09.034_bib0015","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1161\/CIR.0b013e318256f1e0","volume":"126","author":"Jneid","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.medcli.2013.09.034_bib0020","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1093\/eurheartj\/ehs215","article-title":"ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation","volume":"33","author":"Steg","year":"2012","journal-title":"Eur Heart J"},{"key":"10.1016\/j.medcli.2013.09.034_bib0025","doi-asserted-by":"crossref","first-page":"2999","DOI":"10.1093\/eurheartj\/ehr236","volume":"32","author":"Hamm","year":"2011","journal-title":"Eur Heart J"},{"key":"10.1016\/j.medcli.2013.09.034_bib0030","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1136\/hrt.2010.206508","article-title":"Antiplatelet therapy in percutaneous coronary intervention: Is variability of response clinically relevant","volume":"97","author":"Curzen","year":"2011","journal-title":"Heart"},{"key":"10.1016\/j.medcli.2013.09.034_bib0035","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1016\/S0002-9149(02)02718-2","article-title":"Frequency of aspirin resistance in patients with congestive heart failure treated with antecedent aspirin","volume":"90","author":"Sane","year":"2002","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.medcli.2013.09.034_bib0040","doi-asserted-by":"crossref","first-page":"2420","DOI":"10.1093\/eurheartj\/ehl275","article-title":"Low response to clopidogrel is associated with cardiovascular outcome after coronary stent implantation","volume":"27","author":"Geisler","year":"2006","journal-title":"Eur Heart J"},{"key":"10.1016\/j.medcli.2013.09.034_bib0045","doi-asserted-by":"crossref","first-page":"2373","DOI":"10.1056\/NEJMra052717","article-title":"Low-dose aspirin for the prevention of atherothrombosis","volume":"353","author":"Patrono","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.medcli.2013.09.034_bib0050","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1136\/bmj.324.7329.71","article-title":"Collaborative metaanalysis of randomized trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients","volume":"324","year":"2002","journal-title":"BMJ"},{"key":"10.1016\/j.medcli.2013.09.034_bib0055","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1136\/bmj.316.7141.1337","article-title":"ISIS- 2: 10 year survival among patients with suspected acute myocardial infarction in randomised comparison of intravenous streptokinase, oral aspirin, both, or neither The ISIS-2 (Second InternationalStudy of Infarct Survival) Collaborative Group","volume":"316","author":"Baigent","year":"1998","journal-title":"BMJ"},{"key":"10.1016\/j.medcli.2013.09.034_bib0060","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1056\/NEJM198907203210301","article-title":"Final report on the aspirin component of the ongoing Physicians\u2019 Health Study. Steering Committee of the Physicians\u2019 Health Study Research Group","volume":"321","year":"1989","journal-title":"N Engl J Med"},{"key":"10.1016\/j.medcli.2013.09.034_bib0065","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1056\/NEJM199704033361401","article-title":"Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men","volume":"336","author":"Ridker","year":"1997","journal-title":"N Engl J Med"},{"key":"10.1016\/j.medcli.2013.09.034_bib0070","doi-asserted-by":"crossref","first-page":"2962","DOI":"10.1093\/eurheartj\/ehr423","article-title":"Aspirin for primary prevention of vascular events in women: Individualized prediction of treatment effect","volume":"32","author":"Dorresteijn","year":"2011","journal-title":"Eur Heart J"},{"key":"10.1016\/j.medcli.2013.09.034_bib0075","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1001\/archinternmed.2011.628","article-title":"Effect of aspirin on vascular and nonvascular outcomes meta-analysis of randomized controlled trials","volume":"172","author":"Seshasai","year":"2012","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.medcli.2013.09.034_bib0080","doi-asserted-by":"crossref","first-page":"376721","DOI":"10.1155\/2012\/376721","article-title":"Variability in the responsiveness to low-dose aspirin: Pharmacological and disease-related mechanisms","volume":"2012","author":"Rocca","year":"2012","journal-title":"Thrombosis"},{"key":"10.1016\/j.medcli.2013.09.034_bib0085","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1161\/01.STR.24.3.345","article-title":"Aspirin resistance and failure in cerebral infarction","volume":"24","author":"Helgasson","year":"1993","journal-title":"Stroke"},{"key":"10.1016\/j.medcli.2013.09.034_bib0090","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.ahj.2006.10.040","article-title":"Prevalence of persistent platelet reactivity despite use of aspirin: A systematic review","volume":"153","author":"Hovens","year":"2007","journal-title":"Am Heart J"},{"key":"10.1016\/j.medcli.2013.09.034_bib0095","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/S0140-6736(06)68040-9","article-title":"Aspirin resistance","volume":"367","author":"Hankey","year":"2006","journal-title":"Lancet"},{"key":"10.1016\/j.medcli.2013.09.034_bib0100","doi-asserted-by":"crossref","first-page":"2667","DOI":"10.1093\/eurheartj\/ehl334","article-title":"A systematic review and meta-analysis on the hazards of discontinuing or not adhering to aspirin among 50,279 patients at risk for coronary artery disease","volume":"27","author":"Biondi-Zoccai","year":"2006","journal-title":"Eur Heart J"},{"key":"10.1016\/j.medcli.2013.09.034_bib0105","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/nrcardio.2010.185","article-title":"Antiplatelet therapy: Clopidogrel-PPI interaction, an ongoing controversy","volume":"8","author":"Gurbel","year":"2011","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.medcli.2013.09.034_bib0110","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1111\/j.1538-7836.2004.00836.x","article-title":"Platelet activation in type 2 diabetes mellitus","volume":"2","author":"Ferroni","year":"2004","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.medcli.2013.09.034_bib0115","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1161\/01.CIR.94.1.19","article-title":"Modulation of oxidant stress in vivo in chronic cigarette smokers","volume":"94","author":"Reilly","year":"1996","journal-title":"Circulation"},{"key":"10.1016\/j.medcli.2013.09.034_bib0120","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1160\/TH05-07-0516","article-title":"Polymorphisms of COX-1 and GPVI associate with the antiplatelet effect of aspirin in coronary artery disease patients","volume":"95","author":"Lep\u00e4ntalo","year":"2006","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.medcli.2013.09.034_bib0125","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1111\/j.1365-2125.2008.03183.x","article-title":"Pharmacogenetics of aspirin resistance: A comprehensive systematic review","volume":"66","author":"Goodman","year":"2008","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.medcli.2013.09.034_bib0130","doi-asserted-by":"crossref","first-page":"71","DOI":"10.2165\/11318100-000000000-00000","article-title":"Effect of obesity on the pharmacokinetics of drugs in humans","volume":"49","author":"Hanley","year":"2010","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.medcli.2013.09.034_bib0135","doi-asserted-by":"crossref","first-page":"3671","DOI":"10.1210\/jc.2008-0222","article-title":"Primary prevention of cardiovascular disease and type 2 diabetes in patients at metabolic risk: An endocrine society clinical practice guideline","volume":"93","author":"Rosenzweig","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.medcli.2013.09.034_bib0140","doi-asserted-by":"crossref","first-page":"280","DOI":"10.2337\/dc10-1615","article-title":"Low-dose aspirin therapy in patients with type 2 diabetes and reduced glomerular filtration rate: Subanalysis from the JPAD trial","volume":"34","author":"Saito","year":"2011","journal-title":"Diabetes Care"},{"key":"10.1016\/j.medcli.2013.09.034_bib0145","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/s00592-005-0186-y","article-title":"Prevalence of aspirin resistance in patients with type 2 diabetes","volume":"42","author":"Fateh-Moghadam","year":"2005","journal-title":"Acta Diabetol"},{"key":"10.1016\/j.medcli.2013.09.034_bib0150","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1016\/j.bcp.2007.12.005","article-title":"Acetylation of prostaglandin H2 synthases by aspirin is inhibited by redox cycling of the peroxidase","volume":"75","author":"Bala","year":"2008","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.medcli.2013.09.034_bib0155","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1111\/j.1538-7836.2012.04723.x","article-title":"The recovery of platelet cyclooxygenase activity explains interindividual variability in responsiveness to low-dose aspirin in patients with and without diabetes","volume":"10","author":"Rocca","year":"2012","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.medcli.2013.09.034_bib0160","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.ijcard.2010.02.025","article-title":"Heterogeneity in platelet cyclooxygenase inhibition by aspirin in coronary artery disease","volume":"150","author":"Lordkipanidz\u00e9","year":"2011","journal-title":"Intl J Cardiol"},{"key":"10.1016\/j.medcli.2013.09.034_bib0165","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1160\/TH10-02-0082","article-title":"24-hour time-dependent aspirin efficacy in patients with stable coronary artery disease","volume":"105","author":"Henry","year":"2011","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.medcli.2013.09.034_bib0170","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1160\/TH11-04-0216","article-title":"Twice daily dosing of aspirin improves platelet inhibition in whole blood in patients with type 2 diabetes mellitus and micro- or macrovascular complications","volume":"106","author":"Spectre","year":"2011","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.medcli.2013.09.034_bib0175","first-page":"CD003186","article-title":"Antiplatelet agents and anticoagulants for hypertension","volume":"3","author":"Lip","year":"2004","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.medcli.2013.09.034_bib0180","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/S0049-3848(03)00419-5","article-title":"Effect of aspirin on constitutive nitric oxide synthase and the bioavailability of NO","volume":"110","author":"Madajka","year":"2003","journal-title":"Thromb Res"},{"key":"10.1016\/j.medcli.2013.09.034_bib0185","doi-asserted-by":"crossref","first-page":"559","DOI":"10.2165\/00002512-200623070-00002","article-title":"Aspirine resistance: Possible roles of cardiovascular risk factors, previous disease history, concomitant medications and hemorrehological variables","volume":"23","author":"Feher","year":"2006","journal-title":"Drugs Aging"},{"key":"10.1016\/j.medcli.2013.09.034_bib0190","article-title":"Antiplatelet agents frente a control or anticuagulations for heart failure in sinus rhythm","volume":"4","author":"Lip","year":"2001","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.medcli.2013.09.034_bib0195","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.ahj.2004.03.010","article-title":"The Warfarin\/Aspirin Study in Heart Failure (WASH): A randomized trial comparing antithrombotic strategies for patients with heart failure","volume":"148","author":"Cleland","year":"2004","journal-title":"Am Heart J"},{"key":"10.1016\/j.medcli.2013.09.034_bib0200","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1016\/j.jacc.2011.03.049","article-title":"Aspirin extrusion from human platelets through multidrug resistence protein-4-mediated transport (MRP-4)","volume":"58","author":"Mattiello","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.medcli.2013.09.034_bib0205","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1056\/NEJMoa010746","article-title":"Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation","volume":"345","author":"Yusuf","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.medcli.2013.09.034_bib0210","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.ahj.2007.04.014","article-title":"Clopidogrel nonresponsiveness in patients undergoing percutaneous coronary intervention with stenting: A systematic review and meta-analysis","volume":"154","author":"Snoep","year":"2007","journal-title":"Am Heart J"},{"key":"10.1016\/j.medcli.2013.09.034_bib0215","doi-asserted-by":"crossref","first-page":"965","DOI":"10.2147\/VHRM.S6787","article-title":"Aspirin and clopidogrel hyporesponsiveness and nonresponsiveness in patients with coronary artery stenting","volume":"5","author":"Sharma","year":"2009","journal-title":"Vasc Health Risk Manag"},{"key":"10.1016\/j.medcli.2013.09.034_bib0220","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1161\/CIRCULATIONAHA.109.885194","article-title":"Cytochrome 2C19*17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement","volume":"121","author":"Sibbing","year":"2010","journal-title":"Circulation"},{"key":"10.1016\/j.medcli.2013.09.034_bib0225","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1016\/S0140-6736(10)61274-3","article-title":"Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor frente a clopidogrel for acute coronary syndromes: A genetic substudy of the PLATO trial","volume":"376","author":"Wallentin","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.medcli.2013.09.034_bib0230","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1056\/NEJMoa0809171","article-title":"Cytochrome p-450 polymorphisms and response to clopidogrel","volume":"360","author":"Mega","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.medcli.2013.09.034_bib0235","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1016\/S0140-6736(10)61273-1","article-title":"Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON-TIMI 38 trial: A pharmacogenetic analysis","volume":"376","author":"Mega","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.medcli.2013.09.034_bib0240","doi-asserted-by":"crossref","first-page":"2348","DOI":"10.1253\/circj.CJ-12-0476","article-title":"Effect of cytochrome P450 2C19 polymorphism on targer lesion outcome after drug eluting stent implantation in Japanese patients receiving clopidogrel","volume":"76","author":"Nishio","year":"2012","journal-title":"Circ J"},{"key":"10.1016\/j.medcli.2013.09.034_bib0245","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/j.jacc.2006.10.050","article-title":"Increased risk in patients with high platelet aggregation receiving chronic clopidogrel therapy undergoing percutaneous coronary intervention. Is the current antiplatelet therapy adequate?","volume":"49","author":"Bliden","year":"2007","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.medcli.2013.09.034_bib0250","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1016\/j.jacc.2008.06.038","volume":"52","author":"Patti","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.medcli.2013.09.034_bib0255","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1001\/jama.2011.1332","article-title":"High residual platelet reactivity after clopidogrel loading and long-term cardiovascular events patients with acute coronary syndromes undergoing PCI","volume":"306","author":"Parodi","year":"2011","journal-title":"JAMA"},{"key":"10.1016\/j.medcli.2013.09.034_bib0260","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1056\/NEJMoa0909475","article-title":"Dose comparisons of clopidogrel and aspirin in acute coronary syndromes","volume":"363","author":"Mehta","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.medcli.2013.09.034_bib0265","first-page":"1097","article-title":"Standard-vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: The GRAVITAS randomized trial","volume":"305","author":"Price","year":"2011"},{"key":"10.1016\/j.medcli.2013.09.034_bib0270","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.jacc.2005.08.058","article-title":"Aspirin and clopidogrel drug response in patients undergoing percutaneous coronary intervention: The role of dual drug resistance","volume":"47","author":"Lev","year":"2006","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.medcli.2013.09.034_bib0275","doi-asserted-by":"crossref","first-page":"2553","DOI":"10.1161\/CIRCULATIONAHA.109.851949","article-title":"Cytochrome P450 genetic polymorphisms and the response to prasugrel: Relationship to pharmacokinetic, pharmacodynamic, and clinical outcomes","volume":"119","author":"Mega","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.medcli.2013.09.034_bib0280","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1056\/NEJMoa0904327","article-title":"Ticagrelor versus clopidogrel in patients with acute coronary syndromes","volume":"361","author":"Wallentin","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.medcli.2013.09.034_bib0285","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1007\/s11886-011-0206-1","article-title":"Thienopyridine-associated drug-drug interactions: Pharmacologic mechanisms and clinical relevance","volume":"13","author":"Hulot","year":"2011","journal-title":"Curr Cardiol Rep"},{"key":"10.1016\/j.medcli.2013.09.034_bib0290","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1056\/NEJMoa0706482","article-title":"Prasugrel frente a clopidogrel in patients with acute coronary syndromes","volume":"357","author":"Wiviott","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.medcli.2013.09.034_bib0295","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1056\/NEJMoa1205512","article-title":"Prasugrel versus clopidogrel for acute coronary syndromes without revascularization","volume":"367","author":"Roe","year":"2012","journal-title":"N Engl J Med"}],"container-title":["Medicina Cl\u00ednica"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025775313007525?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025775313007525?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,8,4]],"date-time":"2019-08-04T19:16:25Z","timestamp":1564946185000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0025775313007525"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,9]]},"references-count":59,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2014,9]]}},"alternative-id":["S0025775313007525"],"URL":"https:\/\/doi.org\/10.1016\/j.medcli.2013.09.034","relation":{},"ISSN":["0025-7753"],"issn-type":[{"value":"0025-7753","type":"print"}],"subject":[],"published":{"date-parts":[[2014,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antiagregaci\u00f3n: resistencia a f\u00e1rmacos tradicionales y papel de los nuevos antiplaquetarios","name":"articletitle","label":"Article Title"},{"value":"Medicina Cl\u00ednica","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.medcli.2013.09.034","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier Espa\u00f1a, S.L. All rights reserved.","name":"copyright","label":"Copyright"}]}}